Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms

JCI Insight. 2018 Nov 2;3(21):e99470. doi: 10.1172/jci.insight.99470.

Abstract

Hypertriglyceridemia is an independent risk factor for cardiovascular disease. Dietary interventions based on protein restriction (PR) reduce circulating triglycerides (TGs), but underlying mechanisms and clinical relevance remain unclear. Here, we show that 1 week of a protein-free diet without enforced calorie restriction significantly lowered circulating TGs in both lean and diet-induced obese mice. Mechanistically, the TG-lowering effect of PR was due, in part, to changes in very low-density lipoprotein (VLDL) metabolism both in liver and peripheral tissues. In the periphery, PR stimulated VLDL-TG consumption by increasing VLDL-bound APOA5 expression and promoting VLDL-TG hydrolysis and clearance from circulation. The PR-mediated increase in Apoa5 expression was controlled by the transcription factor CREBH, which coordinately regulated hepatic expression of fatty acid oxidation-related genes, including Fgf21 and Ppara. The CREBH-APOA5 axis activation upon PR was intact in mice lacking the GCN2-dependent amino acid-sensing arm of the integrated stress response. However, constitutive hepatic activation of the amino acid-responsive kinase mTORC1 compromised CREBH activation, leading to blunted APOA5 expression and PR-recalcitrant hypertriglyceridemia. PR also contributed to hypotriglyceridemia by reducing the rate of VLDL-TG secretion, independently of activation of the CREBH-APOA5 axis. Finally, a randomized controlled clinical trial revealed that 4-6 weeks of reduced protein intake (7%-9% of calories) decreased VLDL particle number, increased VLDL-bound APOA5 expression, and lowered plasma TGs, consistent with mechanistic conservation of PR-mediated hypotriglyceridemia in humans with translational potential as a nutraceutical intervention for dyslipidemia.

Keywords: Lipoproteins; Metabolism.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apolipoprotein A-V
  • Apolipoproteins / metabolism
  • Cyclic AMP Response Element-Binding Protein
  • Diet, Protein-Restricted / adverse effects*
  • Diet, Protein-Restricted / methods
  • Female
  • Humans
  • Hydrolysis
  • Hypertriglyceridemia / complications
  • Hypertriglyceridemia / epidemiology
  • Lipid Metabolism
  • Lipoproteins, VLDL / blood*
  • Lipoproteins, VLDL / metabolism
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Mechanistic Target of Rapamycin Complex 1 / metabolism*
  • Mice
  • Protein-Serine-Threonine Kinases / deficiency
  • Protein-Serine-Threonine Kinases / metabolism*
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Triglycerides / blood*
  • Triglycerides / metabolism

Substances

  • Apoa5 protein, mouse
  • Apolipoprotein A-V
  • Apolipoproteins
  • Creb3l3 protein, mouse
  • Cyclic AMP Response Element-Binding Protein
  • Lipoproteins, VLDL
  • Triglycerides
  • very low density lipoprotein triglyceride
  • Eif2ak4 protein, mouse
  • Mechanistic Target of Rapamycin Complex 1
  • Protein-Serine-Threonine Kinases